Jaguar Health Inc represents a set of core values and a corporate philosophy focused on innovation, sustainability, and healthcare advancements. With a strong commitment to improving human and animal health, the company dedicates itself to developing and commercializing novel plant-based solutions and veterinary products. Jaguar Health Inc places great emphasis on creating value for patients, providers, and shareholders through its portfolio of natural product candidates. Rooted in scientific research and environmental stewardship, the company strives to contribute to the well-being of communities worldwide, serving as a leading force in promoting health and wellness through its innovative products and socially responsible practices.

Jaguar Health Inc is primarily present in the United States.

Some significant milestones achieved by Jaguar Health Inc include the development and commercialization of Mytesi, an FDA-approved drug for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS. The company has also established partnerships and collaborations with various organizations to expand the availability of Mytesi globally. Additionally, Jaguar Health Inc has made advancements in its pipeline, focusing on potential therapeutic options for various gastrointestinal indications. The company continues to drive innovation and aims to provide effective treatments for patients suffering from gastrointestinal disorders.

Jaguar Health Inc is a pharmaceutical company focused on developing and commercializing innovative products for people and animals with gastrointestinal distress. Founded in 2013 and headquartered in San Francisco, California, Jaguar Health Inc is committed to improving patient care through its natural and plant-based formulas. The company's flagship product, Mytesi, is an FDA-approved prescription medicine for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. With a strong emphasis on sustainability and ethical practices, Jaguar Health Inc aims to provide effective solutions while ensuring the wellbeing of both patients and the planet.

The main competitors of Jaguar Health Inc in the market include larger pharmaceutical companies such as Pfizer, Johnson & Johnson, and Merck & Co. These established companies have a strong presence and offer a wide range of pharmaceutical products. However, Jaguar Health Inc differentiates itself by focusing on the development of natural, plant-based pharmaceuticals and treatments, which cater to a specific niche market. Despite facing competition from these industry giants, Jaguar Health Inc's unique approach and dedication to natural medicine position it as a viable alternative in the healthcare industry.

Jaguar Health Inc is primarily active in the industries of pharmaceuticals and healthcare.

The business model of Jaguar Health Inc focuses on developing and commercializing novel, plant-based pharmaceutical and nutraceutical products derived from plants and botanical sources. The company aims to address unmet medical needs in both human and animal health through its drug discovery and development programs. Jaguar Health Inc utilizes scientific research and partnerships to identify promising botanical compounds and develop them into potential therapies. By leveraging the benefits of natural products, the company aims to provide innovative and sustainable solutions to improve the health and well-being of patients.

Коефициентът на цена спрямо печалбата (КЦП) на Jaguar Health е -0,12.

Коефициентът на цена към оборот (KUV) на Jaguar Health е 0,03.

AlleAktien качественият резултат за Jaguar Health е 5/10.

очаквана Jaguar Health оборотът е 13,64 млн. USD.

очаквана Jaguar Health печалба е -3,72 млн. USD.

Jaguar Health Inc is a biopharmaceutical company that focuses on the development and commercialization of natural medicines from plant sources. The company is divided into several business areas to ensure optimal alignment with the respective target markets.

Jaguar Health разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Jaguar Health в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Jaguar Health е US47010C4096.

WKN на Jaguar Health е A2PLYX.

Тикерът на Jaguar Health е JAGX.

През последните 12 месеца Jaguar Health изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Jaguar Health да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Jaguar Health в момента е .

Jaguar Health изплаща дивидент на тримесечие. Той се разпределя в месеците .

Jaguar Health платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Jaguar Health се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Jaguar Health на 31.07.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 31.07.2024 г..

Последното дивидентно плащане беше извършено на 31.07.2024 г..

През година 2023 Jaguar Health изплати 0 USD под формата на дивиденти.

Дивидентите от Jaguar Health се изплащат в USD.